Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging

被引:99
作者
Pellegriti, G
Leboulleux, S
Baudin, E
Bellon, N
Scollo, C
Travagli, JP
Schlumberger, M
机构
[1] Inst Gustave Roussy, Serv Med Nucl & Cancerol Endocrieme, F-94805 Villejuif, France
[2] Inst Gustave Roussy, Dept Biostat & Sante Publ, F-94805 Villejuif, France
[3] Inst Gustave Roussy, Serv Chirurg Gen, F-94805 Villejuif, France
关键词
medullary thyroid cancer; calcitonin; prognostic factors; relapse-free survival;
D O I
10.1038/sj.bjc.6600930
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Imaging-detected relapses are observed in a significant proportion of patients with medullary thyroid carcinoma (MTC) with normal postoperative imaging studies. The aim of this study was to search for prognostic factors of imaging-detected relapse. This retrospective study was performed in 63 consecutive MTC patients with normal postoperative medical imaging. After surgery, the basal calcitonin (CT) level was undetectable in 35 patients and elevated in 28. During follow-up, 18 patients developed a clinical or imaging-detected relapse (29%) in the neck and/or at distant sites: 15 had an elevated postoperative basal CT level and three had an undetectable postoperative basal CT level. At multivariate analysis, the significant parameters predictive of imaging-detected relapse were the postoperative plasma CT level and the tumour extension (pT). The 3- and 5-year relapse-free survival rates were 94 and 90% in patients with an undetectable postoperative basal CT level, and 78 and 61% in patients with a detectable basal CT level (P<0.05). The 3- and 5-year relapse-free survival rates were 92 and 85% in the pT1 - 3 patients, and 57 and 46% in the pT4 patients (P<0.01). These results show that postoperative CT level and tumour extension are critical prognostic factors for the identification of patients at a high risk of relapse.
引用
收藏
页码:1537 / 1542
页数:6
相关论文
共 28 条
[11]   Long-term results of reoperation and localizing studies in patients with persistent or recurrent medullary thyroid cancer [J].
Kebebew, E ;
Kikuchi, S ;
Duh, QY ;
Clark, OH .
ARCHIVES OF SURGERY, 2000, 135 (08) :895-899
[12]  
Kebebew E, 2000, CANCER-AM CANCER SOC, V88, P1139, DOI 10.1002/(SICI)1097-0142(20000301)88:5<1139::AID-CNCR26>3.0.CO
[13]  
2-Z
[14]  
Machens A, 2000, CANCER, V88, P1909, DOI 10.1002/(SICI)1097-0142(20000415)88:8<1909::AID-CNCR21>3.0.CO
[15]  
2-A
[16]   Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients [J].
Modigliani, E ;
Cohen, R ;
Campos, JM ;
Conte-Devolx, B ;
Maes, B ;
Boneu, A ;
Schlumberger, M ;
Bigorgne, JC ;
Dumontier, P ;
Leclerc, L ;
Corcuff, B ;
Guilhem, I .
CLINICAL ENDOCRINOLOGY, 1998, 48 (03) :265-273
[17]  
Moley JF, 1998, J INTERN MED, V243, P521
[18]   PROGNOSTIC FACTORS IN MEDULLARY-THYROID CARCINOMA - EVALUATION OF 741 PATIENTS FROM THE GERMAN-MEDULLARY-THYROID-CARCINOMA-REGISTER [J].
RAUE, F ;
KOTZERKE, J ;
REINWEIN, D ;
SCHRODER, S ;
ROHER, HD ;
DECKART, H ;
HOFER, R ;
RITTER, M ;
SEIF, F ;
BUHR, H ;
BEYER, J ;
SCHOBER, O ;
BECKER, W ;
NEUMANN, H ;
CALVI, J ;
WINTER, J ;
VOGT, H .
CLINICAL INVESTIGATOR, 1993, 71 (01) :7-12
[19]   ESTIMATION OF CONFIDENCE-LIMITS FOR CUMULATIVE PROBABILITY OF SURVIVAL IN LIFE TABLE ANALYSIS [J].
ROTHMAN, KJ .
JOURNAL OF CHRONIC DISEASES, 1978, 31 (08) :557-560
[20]   MEDULLARY-THYROID CARCINOMA - PROGNOSTIC FACTORS AND TREATMENT [J].
ROUGIER, P ;
PARMENTIER, C ;
LAPLANCHE, A ;
LEFEVRE, M ;
TRAVAGLI, JP ;
CAILLOU, B ;
SCHLUMBERGER, M ;
LACOUR, J ;
TUBIANA, M .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1983, 9 (02) :161-169